Literature DB >> 17252300

Diagnostic criteria and severity assessment of acute cholecystitis: Tokyo Guidelines.

Masahiko Hirota1, Tadahiro Takada, Yoshifumi Kawarada, Yuji Nimura, Fumihiko Miura, Koichi Hirata, Toshihiko Mayumi, Masahiro Yoshida, Steven Strasberg, Henry Pitt, Thomas R Gadacz, Eduardo de Santibanes, Dirk J Gouma, Joseph S Solomkin, Jacques Belghiti, Horst Neuhaus, Markus W Büchler, Sheung-Tat Fan, Chen-Guo Ker, Robert T Padbury, Kui-Hin Liau, Serafin C Hilvano, Giulio Belli, John A Windsor, Christos Dervenis.   

Abstract

The aim of this article is to propose new criteria for the diagnosis and severity assessment of acute cholecystitis, based on a systematic review of the literature and a consensus of experts. A working group reviewed articles with regard to the diagnosis and treatment of acute cholecystitis and extracted the best current available evidence. In addition to the evidence and face-to-face discussions, domestic consensus meetings were held by the experts in order to assess the results. A provisional outcome statement regarding the diagnostic criteria and criteria for severity assessment was discussed and finalized during an International Consensus Meeting held in Tokyo 2006. Patients exhibiting one of the local signs of inflammation, such as Murphy's sign, or a mass, pain or tenderness in the right upper quadrant, as well as one of the systemic signs of inflammation, such as fever, elevated white blood cell count, and elevated C-reactive protein level, are diagnosed as having acute cholecystitis. Patients in whom suspected clinical findings are confirmed by diagnostic imaging are also diagnosed with acute cholecystitis. The severity of acute cholecystitis is classified into three grades, mild (grade I), moderate (grade II), and severe (grade III). Grade I (mild acute cholecystitis) is defined as acute cholecystitis in a patient with no organ dysfunction and limited disease in the gallbladder, making cholecystectomy a low-risk procedure. Grade II (moderate acute cholecystitis) is associated with no organ dysfunction but there is extensive disease in the gallbladder, resulting in difficulty in safely performing a cholecystectomy. Grade II disease is usually characterized by an elevated white blood cell count; a palpable, tender mass in the right upper abdominal quadrant; disease duration of more than 72 h; and imaging studies indicating significant inflammatory changes in the gallbladder. Grade III (severe acute cholecystitis) is defined as acute cholecystitis with organ dysfunction.

Entities:  

Mesh:

Year:  2007        PMID: 17252300      PMCID: PMC2784516          DOI: 10.1007/s00534-006-1159-4

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


Introduction

Early diagnosis of acute cholecystitis allows prompt treatment and reduces both mortality and morbidity. The accurate diagnosis of typical as well as atypical cases of acute cholecystitis requires specific diagnostic criteria. Acute cholecystitis has a better prognosis than acute cholangitis, but may require immediate management, especially in patients with torsion of the gallbladder and emphysematous, gangrenous, or suppurative cholecystitis. The lack of standard criteria for diagnosis and severity assessment is reflected by the wide range of reported mortality rates in the literature, and this lack makes it impossible to provide standardized optimal treatment guidelines for patients. In these Guidelines we propose specific criteria for the diagnosis and severity assessment of acute cholecystitis, based on the best available evidence and the experts’ consensus achieved at the International Consensus Meeting for the Management of Acute Cholecystitis and Cholangitis, held on April 1–2, 2006, in Tokyo.

Diagnostic criteria for acute cholecystitis

Diagnosis is the starting point of the management of acute cholecystitis, and prompt and timely diagnosis should lead to early treatment and lower mortality and morbidity. Specific diagnostic criteria are necessary to accurately diagnose typical, as well as atypical cases. The Guidelines propose diagnostic criteria for acute cholecystitis (Table 1). C-reactive protein (CRP) is not commonly measured in many countries. However, because acute cholecystitis is usually associatied with an elevation of CRP level by 3 mg/dl or more, CRP was included. Diagnosis of acute cholecystitis by elevation of CRP level (3 mg/dl or more), with ultrasonographic findings suggesting acute cholecystitis, has a sensitivity of 97%, specificity of 76%, and positive predictive value of 95% (level 1b).1 After the discussion during the Tokyo International Consensus Meeting, almost unanimous agreement was achieved on the criteria (Table 2). However, 19% of the panelists from abroad expressed the necessity for minor modifications, because, in the provisional version, the diagnostic criteria did not include technetium hepatobiliery iminodiacetic acid (Tc-HIDA) scan as an item.
Table 1

Diagnostic criteria for acute cholecystitis

A. Local signs of inflammation etc.:
(1) Murphy’s sign, (2) RUQ mass/pain/tenderness
B. Systemic signs of inflammation etc.:
(1) Fever, (2) elevated CRP, (3) elevated WBC count
C. Imaging findings: imaging findings characteristic of acute cholecystitis
Definite diagnosis
(1) One item in A and one item in B are positive
(2) C confirms the diagnosis when acute cholecystitis is suspected clinically

Note: acute hepatitis, other acute abdominal diseases, and chronic cholecystitis should be excluded

Table 2

Answer pad responses on the diagnostic criteria for acute cholecystitis

AgreeAgree, but needs minor modificationsDisagree
Total (n = 110)92%8%0%
Panelists from abroad (n = 21)81%19%0
Japanese panelists (n = 20)100%0%0%
Audience (n = 69)93%7%0%
Diagnostic criteria for acute cholecystitis Note: acute hepatitis, other acute abdominal diseases, and chronic cholecystitis should be excluded Answer pad responses on the diagnostic criteria for acute cholecystitis

Imaging findings of acute cholecystitis

Ultrasonography findings (level 4)2–5 Sonographic Murphy sign (tenderness elicited by pressing the gallbladder with the ultrasound probe) Thickened gallbladder wall (>4 mm; if the patient does not have chronic liver disease and/or ascites or right heart failure) Enlarged gallbladder (long axis diameter >8 cm, short axis diameter >4 cm) Incarcerated gallstone, debris echo, pericholecystic fluid collection Sonolucent layer in the gallbladder wall, striated intramural lucencies, and Doppler signals. Magnetic resonance imaging (MRI) findings (level 1b–4)}6–9 Pericholecystic high signal Enlarged gallbladder Thickened gallbladder wall. Computed tomography (CT) findings (level 3b)10 Thickened gallbladder wall Pericholecystic fluid collection Enlarged gallbladder Linear high-density areas in the pericholecystic fat tissue. Tc-HIDA scans (level 4)11,12 Non-visualized gallbladder with normal uptake and excretion of radioactivity Rim sign (augmentation of radioactivity around the gallbladder fossa).

Severity assessment criteria of acute cholecystitis

Concept of severity grading of acute cholecystitis

Patients with acute cholecystitis may present with a spectrum of disease stages ranging from a mild, self-limited illness to a fulminant, potentially life-threatening illness. In these Guidelines we classify the severity of acute cholecystitis into the following three categories: “mild (grade I)”, “moderate (grade II)”, and “severe (grade III)”. A category for the most severe grade of acute cholecystitis is needed because this grade requires intensive care and urgent treatment (operation and/or drainage) to save the patient’s life. However, the vast majority of patients present with less severe forms of the disease. In these patients, the major practical question regarding management is whether it is advisable to perform cholecystectomy at the time of presentation in the acute phase or whether other strategies of management should be chosen during the acute phase, followed by an interval cholecystectomy. Therefore, to guide the clinician, the severity grading includes a “moderate” group based on criteria predicting when conditions might be unfavorable for cholecystectomy in the acute phase (level 2b–4).13–18 Patients who fall neither into the severe nor the moderate group form the majority of patients with this disease; their disease is suitable for management by cholecystectomy in the acute phase, if comorbidities are not a factor. Definitions of the three grades are given below.

Mild (grade I) acute cholecystitis

Mild acute cholecystitis occurs in a patient in whom there are no findings of organ dysfunction, and there is mild disease in the gallbladder, allowing for cholecystectomy to be performed as a safe and low-risk procedure. These patients do not have a severity index that meets the criteria for “moderate (grade II)” or “severe (grade III)” acute cholecystitis.

Moderate (grade II) acute cholecystitis

In moderate acute cholecystitis, the degree of acute inflammation is likely to be associated with increased operative difficulty to perform a cholecystectomy (level 2b–4).13–18

Severe (grade III) acute cholecystitis

Severe acute cholecystitis is associated with organ dysfunction.

Criteria for the severity assessment of acute cholecystitis

Acute cholecystitis has a better outcome/prognosis than acute cholangitis but requires prompt treatment if gangrenous cholecystitis, emphysematous cholecystitis, or torsion of the gallbladder are present. The progression of acute cholecystitis from the mild/moderate to the severe form means the development of the multiple organ dysfunction syndrome (MODS). Organ dysfunction scores, such as Marshall’s multiple organ dysfunction (MOD) score, and the sequential organ failure assessment (SOFA) score, are sometimes used to evaluate organ dysfunction in critically ill patients. The Guidelines classify the severity of acute cholecystitis into three grades (Tables 3–5): “severe (grade III)”: acute cholecystitis associated with organ dysfunction, “moderate (grade II)”: acute cholecystitis associated with difficulty to perform cholecystectomy due to local inflammation, and “mild (grade I)”: acute cholecystitis which does not meet the criteria of “severe” or “moderate” acute cholecystitis (these patients have acute cholecystitis but no organ dysfunction, and there are mild inflammatory changes in the gallbladder, so that a cholecystectomy can be performed with a low operative risk). Almost unanimous agreement on the criteria was achieved (Tables 6 and 7). When acute cholecystitis is accompanied by acute cholangitis, the criteria for the severity assessment of acute cholangitis should also be taken into account. Being “elderly” per se is not a criterion for severity itself, but indicates a propensity to progress to the severe form, and thus is not included in the criteria for severity assessment.
Table 3

Criteria for mild (grade I) acute cholecystitis

“Mild (grade I)” acute cholecystitis does not meet the criteria of “severe (grade III)” or “moderate (grade II)” acute cholecystitis. Grade I can also be defined as acute cholecystitis in a healthy patient with no organ dysfunction and only mild inflammatory changes in the gallbladder, making cholecystectomy a safe and low-risk operative procedure.
Table 5

Criteria for severe (grade III) acute cholecystitis

“Severe” acute cholecystitis is accompanied by dysfunctions in any one of the following organs/systems
1. Cardiovascular dysfunction (hypotension requiring treatment with dopamine ≧5 µg/kg per min, or any dose of dobutamine)
2. Neurological dysfunction (decreased level of consciousness)
3. Respiratory dysfunction (PaO2/FiO2 ratio <300)
4. Renal dysfunction (oliguria, creatinine >2.0 mg/dl)
5. Hepatic dysfunction (PT-INR >1.5)
6. Hematological dysfunction (platelet count <100 000/mm3)
Table 6

Answer pad responses on the criteria for severe (grade III) acute cholecystitis

AgreeAgree, but needs minor modificationsDisagree
Total (n = 110)90%10%0%
Panelists from abroad (n = 21)95%5%0
Japanese panelists (n = 21)81%19%0%
Audience (n = 68)91%9%0%
Table 7

Answer pad responses on the criteria for moderate (grade II) acute cholecystitis

AgreeAgree, but needs minor modificationsDisagree
Total (n = 109)78%22%0%
Panelists from abroad (n = 22)77%23%0%
Japanese panelists (n = 22)91%9%0%
Audience (n = 65)74%26%0%
Criteria for mild (grade I) acute cholecystitis Criteria for moderate (grade II) acute cholecystitis a Laparoscopic surgery in acute cholecystitis should be performed within 96 h after the onset (level 2b-4)13,14,16 Criteria for severe (grade III) acute cholecystitis Answer pad responses on the criteria for severe (grade III) acute cholecystitis Answer pad responses on the criteria for moderate (grade II) acute cholecystitis

Discussion at the Tokyo International Consensus Meeting

Diagnostic criteria for acute cholecystitis

The clinical diagnosis of acute cholecystitis is traditionally based on the patient’s clinical presentation, and it is confirmed by the imaging findings. Hence, the initial provisional diagnostic criteria for acute cholecystitis comprised: (1) clinical signs and symptoms, (2) laboratory data, and (3) imaging findings. In the discussion on criteria for “clinical signs and symptoms”, 92% of the Japanese panelists agreed, whereas only 65% of the panelists from abroad agreed and 4% disagreed. In regard to the criteria for “laboratory data”, 20% of the Japanese panelists and 39% of the panelists from abroad voted “agree, but needs minor modifications”. After a discussion among the panelists, several changes were made. In regard to the proposed criteria for “imaging findings”, 66%–71% of the Japanese panelists agreed and about 30% of the panelists voted “agree, but needs minor modifications”, and 4% of the panelists from abroad disagreed, because Tc-HIDA scans were not included. Discussion at the International Consensus Meeting led to the reorganization of these categories as: (1) local signs of inflammation, (2) systemic signs of inflammation, and (3) imaging findings. “Suspected diagnosis” in the provisional criteria was deleted, and two conditions for “definite diagnosis” were established in the final diagnostic criteria. After the discussion, 100% of the Japanese panelists and 81% of the panelists from abroad agreed on the final version (refer to Tables 1 and 2; consensus was reached).

Severity assessment criteria for acute cholecystitis

Concerning criteria for severe (grade III) acute cholecystitis, 81% of the Japanese panelists and 95% of the panelists from abroad agreed with the criteria (refer to Tables 5 and 6; consensus was reached). The acute physiology and chronic health evaluation II (APACHE II) score was not included in the assessment criteria, because it is too complicated to apply in community hospitals. The criteria for moderate (grade II) acute cholecystitis can be defined as acute cholecystitis associated with local inflammatory conditions that make cholecystectomy difficult (Steven Strasberg, USA; Dirk J. Gouma, the Netherlands; Henry Pitt, USA; Sheung-Tat Fan and Joseph W.Y. Lau, Hong Kong; Serafin C. Hilvano, Philippines). On the basis of these aspects, the final criteria for moderate (grade II) acute cholecystitis were defined and were agreed on by 91% of the Japanese panelists and 77% of those from abroad (refer to Tables 4 and 7; consensus was reached).
Table 4

Criteria for moderate (grade II) acute cholecystitis

“Moderate” acute cholecystitis is accompanied by any one of the following conditions:
1. Elevated WBC count (>18 000/mm3)
2. Palpable tender mass in the right upper abdominal quadrant
3. Duration of complaints >72 ha
4. Marked local inflammation (biliary peritonitis, pericholecystic abscess, hepatic abscess, gangrenous cholecystitis, emphysematous cholecystitis)

a Laparoscopic surgery in acute cholecystitis should be performed within 96 h after the onset (level 2b-4)13,14,16

The criteria for mild (grade I) acute cholecystitis were agreed on by approximately 90% of both the Japanese panelists and the panelists from abroad (consensus was reached).
  18 in total

1.  Laparoscopic cholecystectomy for acute cholecystitis: how do fever and leucocytosis relate to conversion and complications?

Authors:  S Halachmi; N DiCastro; I Matter; A Cohen; E Sabo; J G Mogilner; J Abrahamson; S Eldar
Journal:  Eur J Surg       Date:  2000-02

2.  Conversion factors in laparoscopic cholecystectomy for acute cholecystitis.

Authors:  J P Teixeira; A C Saraiva; A C Cabral; H Barros; J R Reis; A Teixeira
Journal:  Hepatogastroenterology       Date:  2000 May-Jun

3.  Laparoscopic cholecystectomy for acute cholecystitis: can the need for conversion and the probability of complications be predicted? A prospective study.

Authors:  A Brodsky; I Matter; E Sabo; A Cohen; J Abrahamson; S Eldar
Journal:  Surg Endosc       Date:  2000-08       Impact factor: 4.584

4.  [Laparoscopy or laparotomy in acute cholecystitis (200 cases). Comparison of the results and factors predictive of conversion].

Authors:  J P Araujo-Teixeira; J Rocha-Reis; A Costa-Cabral; H Barros; A C Saraiva; A M Araujo-Teixeira
Journal:  Chirurgie       Date:  1999-11

5.  The rim sign: association with acute cholecystitis.

Authors:  D L Bushnell; S B Perlman; M A Wilson; R E Polcyn
Journal:  J Nucl Med       Date:  1986-03       Impact factor: 10.057

6.  Real-time sonography in suspected acute cholecystitis. Prospective evaluation of primary and secondary signs.

Authors:  P W Ralls; P M Colletti; S A Lapin; P Chandrasoma; W D Boswell; C Ngo; D R Radin; J M Halls
Journal:  Radiology       Date:  1985-06       Impact factor: 11.105

7.  Prospective evaluation of the sonographic Murphy sign in suspected acute cholecystitis.

Authors:  P W Ralls; J Halls; S A Lapin; M F Quinn; U L Morris; W Boswell
Journal:  J Clin Ultrasound       Date:  1982-03       Impact factor: 0.910

8.  [The significance of magnetic resonance cholangiopancreatography in acute cholecystitis].

Authors:  K Ito; N Fujita; Y Noda; G Kobayashi; K Kimura; Y Katakura; A Matsunaga; T Yuki; M Nomura; T Sato; K Ishida; K Uchimi; S Senoo; K Okubo; T Suzuki; D Hirasawa
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  2000-12

9.  Hepatobiliary scanning with 99mTc-PIPIDA in acute cholecystitis.

Authors:  M A Mauro; W H McCartney; J R Melmed
Journal:  Radiology       Date:  1982-01       Impact factor: 11.105

10.  MR imaging in clinically suspected acute cholecystitis. A comparison with ultrasonography.

Authors:  K Håkansson; P Leander; O Ekberg; H O Håkansson
Journal:  Acta Radiol       Date:  2000-07       Impact factor: 1.701

View more
  83 in total

1.  Percutaneous drainage for acute calculous cholecystitis.

Authors:  K Kortram; T S de Vries Reilingh; M J Wiezer; B van Ramshorst; D Boerma
Journal:  Surg Endosc       Date:  2011-06-03       Impact factor: 4.584

2.  Original single-incision laparoscopic cholecystectomy for acute inflammation of the gallbladder.

Authors:  Kazunari Sasaki; Goro Watanabe; Masamichi Matsuda; Masaji Hashimoto
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

3.  Laparoscopic approach to acute abdomen from the Consensus Development Conference of the Società Italiana di Chirurgia Endoscopica e nuove tecnologie (SICE), Associazione Chirurghi Ospedalieri Italiani (ACOI), Società Italiana di Chirurgia (SIC), Società Italiana di Chirurgia d'Urgenza e del Trauma (SICUT), Società Italiana di Chirurgia nell'Ospedalità Privata (SICOP), and the European Association for Endoscopic Surgery (EAES).

Authors:  Ferdinando Agresta; Luca Ansaloni; Gian Luca Baiocchi; Carlo Bergamini; Fabio Cesare Campanile; Michele Carlucci; Giafranco Cocorullo; Alessio Corradi; Boris Franzato; Massimo Lupo; Vincenzo Mandalà; Antonino Mirabella; Graziano Pernazza; Micaela Piccoli; Carlo Staudacher; Nereo Vettoretto; Mauro Zago; Emanuele Lettieri; Anna Levati; Domenico Pietrini; Mariano Scaglione; Salvatore De Masi; Giuseppe De Placido; Marsilio Francucci; Monica Rasi; Abe Fingerhut; Selman Uranüs; Silvio Garattini
Journal:  Surg Endosc       Date:  2012-06-27       Impact factor: 4.584

4.  Does ultrasongraphy predict intraoperative findings at cholecystectomy? An institutional review.

Authors:  Shannon Stogryn; Jennifer Metcalfe; Ashley Vergis; Krista Hardy
Journal:  Can J Surg       Date:  2016-02       Impact factor: 2.089

5.  Novel Use of Long, Large-Caliber, Fenestrated Stents for Endoscopic Transpapillary Gallbladder Stenting for Therapy of Symptomatic Gallbladder Disease.

Authors:  Brooke R Glessing; Rajeev Attam; Stuart K Amateau; Mustafa Tiewala; Yan Bakman; Hashim Nemat; Martin L Freeman; Mustafa A Arain
Journal:  Dig Dis Sci       Date:  2015-08-02       Impact factor: 3.199

6.  Predicting the success of endoscopic transpapillary gallbladder drainage for patients with acute cholecystitis during pretreatment evaluation.

Authors:  Osamu Ogawa; Hiroki Yoshikumi; Naotaka Maruoka; Yusuke Hashimoto; Yui Kishimoto; Watanabe Tsunamasa; Yuichiro Kuroki; Hiroshi Yasuda; Yutaka Endo; Kazuaki Inoue; Makoto Yoshiba
Journal:  Can J Gastroenterol       Date:  2008-08       Impact factor: 3.522

7.  Clinical outcomes of a percutaneous cholecystostomy for acute cholecystitis: a multicentre analysis.

Authors:  Pandanaboyana Sanjay; Devender Mittapalli; Aseel Marioud; Richard D White; Rishi Ram; Afshin Alijani
Journal:  HPB (Oxford)       Date:  2012-11-19       Impact factor: 3.647

Review 8.  Criteria for the diagnosis and severity stratification of acute pancreatitis.

Authors:  Makoto Otsuki; Kazunori Takeda; Seiki Matsuno; Yasuyuki Kihara; Masaru Koizumi; Masahiko Hirota; Tetsuhide Ito; Keisho Kataoka; Motoji Kitagawa; Kazuo Inui; Yoshifumi Takeyama
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

9.  What is the effect of treatment modality on red blood cell distribution width in patients with acute cholecystitis?

Authors:  Pınar Yazıcı; Uygar Demir; Emre Bozdağ; Emre Bozkurt; Gürhan Işıl; Özgür Bostancı; Mehmet Mihmanlı
Journal:  Ulus Cerrahi Derg       Date:  2015-03-01

10.  Outcome of conservative percutaneous cholecystostomy in high-risk patients with acute cholecystitis and risk factors leading to surgery.

Authors:  Won Seok Jang; Jun Uk Lim; Kwang Ro Joo; Jae Myung Cha; Hyun Phil Shin; Sun Hyung Joo
Journal:  Surg Endosc       Date:  2014-12-09       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.